Hikma stock holds steady after director share filing
Published on 08/24/2026 at 21:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Hikma Pharmaceuticals PLC stock held in view on August 24, 2026 after a director and PDMR shareholding notice showed a release of pledge over 2,000,000 ordinary shares and a second pledge over 2,000,000 ordinary shares in Amman, Jordan.
Shareholding notice
The filing, published as the Reuters report on TradingView, lists the transaction date as August 21, 2026 and names Darhold Limited, a person closely associated with Hikma chief executive Ali Al-Husry.
That makes the note useful beyond simple governance watching: 2,000,000 shares were tied to the released pledge and another 2,000,000 shares to the new pledge, a cleanly quantified change that investors can measure against Hikma's share count.
Analyst view
MarketBeat's latest consensus snapshot puts Hikma at a Buy consensus from 6 analysts, with an average target of GBX 2,060 and a reported upside of 25.92% from GBX 1,636 on August 21, 2026.
The same snapshot also shows a recent Citigroup target increase to GBX 1,870 from GBX 1,700 on August 12, 2026, giving the stock a concrete peer-to-peer valuation reference rather than a vague sentiment read.
Product line
Hikma's business still leans on a broad portfolio of injectable, branded and generics medicines, with its generic portfolio and sterile injectables often central to how investors frame margin durability and volume stability.
Stock level
The stock was quoted at GBX 1,636 as of August 21, 2026, and the market's implied upside to the GBX 2,060 consensus target leaves a gap of GBX 424 per share.
Fact box
Company: Hikma Pharmaceuticals PLC
ISIN: GB00B128J450
Ticker: HIK
Exchange: LSE
Price (as of August 21, 2026, 12:44 p.m. ET): GBX 1,636
Market cap: GBX 3.6 billion
Sector / Industry: Health Care / Pharmaceuticals
Index membership: FTSE 100
